A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Birelentinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAI-SHAN10
- Sponsors Dizal Pharmaceutical
Most Recent Events
- 17 Nov 2025 Status changed from not yet recruiting to recruiting.
- 15 Sep 2025 New trial record